Virus Specific T Cell Therapy Articles & Analysis
6 news found
(Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK ...
ByKalaris
(Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the first quarter ended March 31, 2022. The company also shared progress across its virus-specific T cell (VST) programs, with its lead product, posoleucel, ...
ByKalaris
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell ...
ByKalaris
” “The clinical data presented at EBMT continue to demonstrate the transformative potential of posoleucel, a multi-virus-specific T-cell therapy, for immunocompromised patients,” said Diana Brainard, M.D., Chief Executive Officer, AlloVir. ...
ByKalaris
Three ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of BK viremia in kidney transplant recipients; initial data submitted for presentation in 1H 2022 Advancing two additional ...
ByKalaris
Treatment of AdV infection is posoleucel’s second potential indication to receive RMAT designation Phase 3 registrational study of posoleucel for AdV treatment is now open for enrollment Proof-of-concept study of ALVR106 for the treatment of multiple respiratory viral infections is also open for enrollment AlloVir, a late-clinical stage allogeneic ...
ByKalaris